A. Rashid Qureshi
Karolinska Institutet
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. Rashid Qureshi.
Journal of The American Society of Nephrology | 2003
Mohammed E. Suliman; Olof Heimbürger; Peter Bárány; Björn Anderstam; Roberto Pecoits-Filho; Ernesto Rodríguez Ayala; A. Rashid Qureshi; Ingela Fehrman-Ekholm; Bengt Lindholm; Peter Stenvinkel
Pentosidine is an advanced glycation end-product (AGE), formed by glycosylation and oxidation, that accumulates markedly in end-stage renal disease (ESRD). It has been speculated that AGE and carbonyl stress contributes to long-term complications such as cardiovascular disease (CVD) in ESRD patients. This study determined plasma levels of pentosidine as well as the presence of inflammation (CRP > or = 10 mg/L), clinical CVD (CVD(clin)), and malnutrition (subjective global assessment [SGA] > 1) in a cohort of 191 ESRD patients, median age of 55 yr (range, 23 to 70 yr) and median GFR = 7 ml/min (range, 2 to 17 ml/min), close to start of renal replacement therapy. Fifty-one elderly subjects, median age of 82 yr (range, 71 to 110 yr), with mild renal impairment, median GFR = 67 ml/min (range, 38 to 113 ml/min), were also studied for comparative analysis of plasma pentosidine. The plasma pentosidine content was elevated in all patients compared with the levels in the elderly subjects and were negatively correlated with GFR both in the ESRD patients (Rho = -0.24; P < 0.01; n = 159) and in the elderly subjects (Rho = -0.31; P < 0.05). Moreover, the plasma pentosidine content was correlated with age in the ESRD patients (Rho = 0.26; P < 0.001) and in the elderly subjects (Rho = 0.44; P < 0.001). The 63 malnourished ESRD patients (35%) had a significantly higher (P < 0.05) median plasma pentosidine than the well-nourished patients (39 versus 27 pmol/mg albumin). Similarly, 73 inflamed patients (38%) had a significantly higher (P < 0.001) median pentosidine content compared with 118 non-inflamed patients (37 versus 24 pmol/mg albumin). Also, the plasma pentosidine content showed weak but significant positive correlations with CRP (Rho = 0.28; P < 0.0001), fibrinogen (Rho = 0.23; P < 0.01; n = 126), IL-6 (Rho = 0.22; P < 0.01; n = 169), and soluble vascular cellular adhesion molecule-1 (Rho = 0.38; P < 0.001; n = 74). On the other hand, no significant differences in plasma pentosidine content were noted between the patients with and those without CVD(clin) (32 versus 27 pmol/mg albumin, respectively). Analyses of all-cause mortality, by Kaplan-Meier, showed that mortality was not linked to the plasma pentosidine content. Moreover, survival analysis by the Cox regression model showed that age (P < 0.001), diabetes mellitus (P < 0.01), malnutrition (P < 0.01), and CVD(clin) (P < 0.01) independently predicted poor outcome, whereas an elevated plasma pentosidine content did not. The present study shows that an elevated plasma pentosidine content in ESRD patients is significantly associated with both inflammation and malnutrition and confirms that low residual renal function and high age further contribute to an increased plasma pentosidine content. However, in this small cohort, the plasma pentosidine content did not predict outcome. Thus, accumulation of plasma pentosidine is unlikely to be an appropriate clinically useful marker to predict mortality in ESRD patients.
The American Journal of Clinical Nutrition | 2005
Mohammed E. Suliman; A. Rashid Qureshi; Peter Stenvinkel; Roberto Pecoits-Filho; Peter Bárány; Olof Heimbürger; Björn Anderstam; Ernesto Rodríguez Ayala; José C. Divino Filho; Anders Alvestrand; Bengt Lindholm
BACKGROUND Inflammation and malnutrition are common in chronic kidney disease (CKD) patients, and plasma concentrations of free amino acids (AAs) in these patients are often abnormal. Malnutrition contributes to alterations in AA concentrations. OBJECTIVE The objective was to study the effects of inflammation on plasma AA concentrations. DESIGN Concentrations of plasma AAs, serum albumin, and several inflammatory markers were analyzed in 200 fasting, nondiabetic CKD patients who were close to the start of renal replacement therapy. The nutritional status of these patients was assessed by a subjective global assessment. RESULTS The patients with inflammation [C-reactive protein (CRP) concentrations >10 mg/L] or malnutrition had lower AA concentrations than did the patients with no inflammation or malnutrition. The presence of both inflammation and malnutrition was associated with more marked reductions in AA concentrations than was malnutrition alone. Significant inverse correlations were observed between the plasma concentrations of most of the essential and nonessential AAs and inflammatory markers, whereas serum albumin concentrations were positively correlated with several AA concentrations. A stepwise multivariate regression analysis showed that serum CRP concentrations were independently associated with low concentrations of the sums of both nonessential AAs and all AAs. An analysis of all-cause mortality with a Kaplan-Meier test showed that the patients with higher AA concentrations had significantly better survival than did the patients with lower AA concentrations. CONCLUSIONS Plasma AA concentrations are low in CKD patients with inflammation and are inversely correlated with concentrations of inflammatory markers. Although inflammation and malnutrition are closely related, CRP concentrations were independently associated with low concentrations of the sums of both nonessential AAs and all AAs, which suggests an independent role of inflammation as a cause of low plasma AA concentrations in CKD patients.
Kidney International | 1998
A. Rashid Qureshi; Anders Alvestrand; Anders Danielsson; José Carolino Divino-Filho; Alberto Gutierrez; Bengt Lindholm; Jonas Bergström
Journal of The American Society of Nephrology | 2002
A. Rashid Qureshi; Anders Alvestrand; José Carolino Divino-Filho; Alberto Gutierrez; Olof Heimbürger; Bengt Lindholm; Jonas Bergström
Kidney International | 2000
Mohamed E. Suliman; A. Rashid Qureshi; Peter Bárány; Peter Stenvinkel; José C. Divino Filho; Björn Anderstam; Olof Heimbürger; Bengt Lindholm; Jonas Bergström
American Journal of Kidney Diseases | 2006
Mohamed E. Suliman; Richard J. Johnson; Elvia García-López; A. Rashid Qureshi; Hadi Molinaei; Juan Jesus Carrero; Olof Heimbürger; Peter Bárány; Jonas Axelsson; Bengt Lindholm; Peter Stenvinkel
Nephrology Dialysis Transplantation | 2004
Marcelo Mazza do Nascimento; Roberto Pecoits-Filho; A. Rashid Qureshi; Shirley Y. Hayashi; Roberto Ceratti Manfro; Maria Aparecida Pachaly; Luciana Renner; Peter Stenvinkel; Bengt Lindholm; Miguel C. Riella
Nephrology Dialysis Transplantation | 2006
Mohamed E. Suliman; A. Rashid Qureshi; Olof Heimbürger; Bengt Lindholm; Peter Stenvinkel
American Journal of Kidney Diseases | 2004
Mohamed E. Suliman; Peter Stenvinkel; A. Rashid Qureshi; Peter Bárány; Olof Heimbürger; Björn Anderstam; Anders Alvestrand; Bengt Lindholm
Nephrology Dialysis Transplantation | 2002
Mohamed E. Suliman; Peter Bárány; José C. Divino Filho; A. Rashid Qureshi; Peter Stenvinkel; Olof Heimbürger; Björn Anderstam; Bengt Lindholm; Jonas Bergström